1. Home
  2. BMEA

as of 12-01-2025 12:37pm EST

$1.02
$0.10
-8.56%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Chart Type:
Time Range:
Founded: 2017 Country:
United States
United States
Employees: N/A City: SAN CARLOS
Market Cap: 96.9M IPO Year: 2021
Target Price: $8.71 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.20 EPS Growth: N/A
52 Week Low/High: $0.87 - $7.46 Next Earning Date: 11-04-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered BMEA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 18 hours ago

AI Recommendation

hold
Model Accuracy: 68.71%
68.71%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Biomea Fusion Inc. News

BMEA Breaking Stock News: Dive into BMEA Ticker-Specific Updates for Smart Investing

All BMEA News

Share on Social Networks: